$4 MILLION PARTNERSHIP TO REDUCE BARRIERS TO THE DEVELOPMENT OF PERSONALIZED MEDICINE IN ONCOLOGY
• Make Canada’s rich scientific resources accessible to the research community
• Create a comprehensive cancer database of tissue samples, genomic data and clinical
data from the cancer patient population
• Match patients to available clinical trials based on the profile of their cancer
Moncton, New Brunswick - April 18, 2016 - At an announcement made earlier today at the Dr. Georges-L.-Dumont University Hospital Centre, Merck, known as MSD outside the United States and Canada, confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help bring innovative precision medicine to Canadians living with cancer.